Abstract
COVID-19 shows an unexplained, strong male bias for severity and mortality. Loss of Y (LOY) in myeloid cells is a risk factor candidate in COVID-19 because of associations with many age-related diseases and its effect on transcription of immune genes. We report the highest levels of LOY in cells that are crucial for the development of severe COVID-19 phenotype, such as low-density neutrophils, granulocytes, and monocytes reaching 46%, 32%, and 29%, respectively, from men with critical COVID-19 (n=139). LOY in sorted subpopulations of leukocytes correlated with increased thrombocyte count, thromboembolic events, invasive mechanical ventilation and a history of vessel disease. In recovered patients, LOY decreased in whole blood and peripheral blood mononuclear cells. Moreover, sc-RNA-seq analysis of CD14+ monocytes from 30 COVID-19 males and 34 controls revealed pervasive transcriptional downregulation in LOY-cells, notably affecting HLA class I and II genes important for antigen presentation. The data support a link between LOY and emergency myelopoiesis as well as the role of LOY in modulation of COVID-19 severity. Our results might also be relevant for other viral infections showing similar male bias.
Competing Interest Statement
J.P.D. is a cofounder and shareholder in Cray Innovation AB.
Funding Statement
This study was supported by grants from the Science for Life Laboratory/KAW via National COVID-19 research, Swedish Heart-Lung Foundation, Swedish Cancer Society, the Swedish Research Council, Hjarnfonden, Alzheimerfonden, Konung Gustav V:s och Drottning Viktorias Frimurarestiftelse, and the Foundation for Polish Science under the International Research Agendas Programme (grant number MAB/2018 /6; co-financed by the European Union under the European Regional Development Fund) to J.P.D.; SciLifeLab/KAW national COVID-19 research program project grant to MH (KAW 2020.0182 and KAW 2020.0241), the Swedish Heart Lung Foundation to M.H. (20190639, 20190637 and 20210089) and the Swedish Research Council [2014-02569, 2014-07606, and 2016-02606 (the latter to J.D.J.)] as well as The Swedish Kidney Foundation (F2020-0054) to R.F. This study was also supported by grants from the SciLifeLab National COVID-19 Research Program, financed by the Knut and Alice Wallenberg Foundation [2020.0182 and 2020.0241, the Swedish Research Council (#2021-06545)] and the Swedish State Support for Clinical Research (ALFGBG-717531) to M.G.; J.O.W was supported by KAW Foundation as part of the National Bioinformatics Infrastructure Sweden at SciLifeLab. Single cell RNA sequencing was performed at SNP&SEQ facilities at Uppsala University and SciLifeLab. SNP&SEQ is part of the National Genomics Infrastructure (NGI) Sweden supported by the Swedish Research Council and the Knut and Alice Wallenberg Foundation. Support by NBIS (National Bioinformatics Infrastructure Sweden) is gratefully acknowledged. Data handling and computations were enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) partially funded by the Swedish Research Council (#2018-05973).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The local research ethics committee in Uppsala and Gothenburg gave ethical approval for this work. The Bioethics Committee at the Medical University of Gdansk gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* shared senior authors
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
